JP2019529566A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529566A5
JP2019529566A5 JP2019538108A JP2019538108A JP2019529566A5 JP 2019529566 A5 JP2019529566 A5 JP 2019529566A5 JP 2019538108 A JP2019538108 A JP 2019538108A JP 2019538108 A JP2019538108 A JP 2019538108A JP 2019529566 A5 JP2019529566 A5 JP 2019529566A5
Authority
JP
Japan
Prior art keywords
ubenimex
administered
medicament
inhibitor
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019538108A
Other languages
English (en)
Japanese (ja)
Other versions
JP7022136B2 (ja
JP2019529566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/054087 external-priority patent/WO2018064373A1/en
Publication of JP2019529566A publication Critical patent/JP2019529566A/ja
Publication of JP2019529566A5 publication Critical patent/JP2019529566A5/ja
Application granted granted Critical
Publication of JP7022136B2 publication Critical patent/JP7022136B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019538108A 2016-09-28 2017-09-28 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物 Expired - Fee Related JP7022136B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662400963P 2016-09-28 2016-09-28
US62/400,963 2016-09-28
US201762460606P 2017-02-17 2017-02-17
US62/460,606 2017-02-17
US201762469722P 2017-03-10 2017-03-10
US62/469,722 2017-03-10
PCT/US2017/054087 WO2018064373A1 (en) 2016-09-28 2017-09-28 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Publications (3)

Publication Number Publication Date
JP2019529566A JP2019529566A (ja) 2019-10-17
JP2019529566A5 true JP2019529566A5 (https=) 2020-07-02
JP7022136B2 JP7022136B2 (ja) 2022-02-17

Family

ID=61760848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019538108A Expired - Fee Related JP7022136B2 (ja) 2016-09-28 2017-09-28 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物

Country Status (6)

Country Link
US (2) US10588880B2 (https=)
EP (1) EP3518918A4 (https=)
JP (1) JP7022136B2 (https=)
KR (1) KR102399254B1 (https=)
CN (1) CN109862888B (https=)
WO (1) WO2018064373A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102399254B1 (ko) 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
US20210369693A1 (en) * 2017-11-28 2021-12-02 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
WO2019209738A1 (en) * 2018-04-24 2019-10-31 Ph Pharma Co., Ltd. Use of neutrophil elastase inhibitors in liver disease
EP3811937A1 (en) * 2019-10-24 2021-04-28 Sorbonne Universite Compounds for use in the prevention and/or treatment of non-alcoholic fatty liver disease
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029547A (en) 1974-07-01 1977-06-14 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
US4052449A (en) 1974-07-01 1977-10-04 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
JPH0759507B2 (ja) * 1989-02-23 1995-06-28 日本化薬株式会社 骨髄異形成症候群治療剤
CN1098249C (zh) * 1995-06-21 2003-01-08 国家医药管理局四川抗菌素工业研究所 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途
WO2005000227A2 (en) 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
NZ570381A (en) * 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
JP2009109426A (ja) * 2007-10-31 2009-05-21 Sysmex Corp 検体前処理液、ウイルス測定用キット及びウイルス検出方法
US9072732B2 (en) * 2010-11-22 2015-07-07 The Regents Of The University Of California Indication for use of niacin (nicotinic acid) for treatment and reversal of fatty liver disease
US8962687B2 (en) * 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
WO2013142369A1 (en) 2012-03-23 2013-09-26 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pulmonary hypertension with leukotriene inhibitors
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
WO2014106846A2 (en) * 2013-01-03 2014-07-10 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
SI3043865T1 (sl) * 2013-09-11 2021-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
HUE045209T2 (hu) * 2013-12-04 2019-12-30 Galmed Res & Development Ltd Aramchol-sók
WO2016149126A1 (en) 2015-03-13 2016-09-22 The Board Of Trustees Of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
CN104784178B (zh) * 2015-05-08 2017-04-12 重庆医科大学 尼克酰胺作为有效成分在制备乙型肝炎治疗药物中的用途
CN104887655A (zh) * 2015-06-12 2015-09-09 上海来益生物药物研究开发中心有限责任公司 乌苯美司在制备用于预防和治疗炎症疾病和与炎症相关的感染疾病的药物制剂中的应用
HK1257929A1 (zh) 2015-11-06 2019-11-01 Gemphire Therapeutics Inc. 治疗混合性血脂异常
KR102399254B1 (ko) 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
US20210369693A1 (en) 2017-11-28 2021-12-02 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Similar Documents

Publication Publication Date Title
JP2019529566A5 (https=)
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
ES2767084T3 (es) Nuevo uso
JP2018514534A5 (https=)
CA2568443A1 (en) Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihistamines
HRP20160189T1 (hr) Liječenje crohnove bolesti lakvinimodom
JP2015038135A5 (https=)
EP2797584B1 (en) Combinations of diacerein and non-steroidal inflammation drugs
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
CA2956257A1 (en) Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
RU2008121767A (ru) Пероральная фармацевтическая лекарственная форма, содержащая в качестве активных ингредиентов ингибитор протонного насоса совместно с ацетилсалициловой кислотой
US7303761B2 (en) Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin
HRP20211826T1 (hr) Čvrste farmaceutske kompozicije koje sadrže inhibitor integraze
BG102669A (bg) Метод за лечение и фармацевтичен състав
JP2008533127A5 (https=)
JP2024533756A5 (https=)
Kaur et al. Diacerein, its beneficial impact on chondrocytes and notable new clinical applications
IL274414B1 (en) Oral rifamycin sv compositions
JP2019218379A5 (https=)
EA015304B1 (ru) Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением
JP2021504479A5 (https=)
CN100502870C (zh) 含有瑞舒伐他汀或匹伐他汀和b族维生素的药物组合物
AR068560A1 (es) Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroide y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota artritis gotosa y enfermedades relacionadas
RU2020121222A (ru) Агонисты fxr для лечения заболеваний печени
US11648240B2 (en) Pharmaceutical composition comprising famotidine, lidocaine and melatonin